Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,385,015
-$395,924 QoQ
Shares Held
40,868
-26.5% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#104
of 197 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SEI INVESTMENTS CO holds $1,244,853,716 across 210 Biotechnology names. NAMS ranks #65 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
255,073 | $236,649,076 | |
| 2 | INSM |
INSMED Inc
|
1,015,870 | $108,312,059 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
129,981 | $64,565,461 | |
| 4 | EXEL |
Exelixis, Inc.
|
1,166,715 | $63,480,962 | |
| 5 | ASND |
Ascendis Pharma A/S
|
237,869 | $63,444,419 | |
| 6 | INCY |
Incyte Corp
|
498,013 | $56,454,752 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
551,116 | $43,135,848 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
60,441 | $37,687,380 |
All Filings in NAMS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,385,015 | 40,868 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,780,939 | 55,637 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,439,682 | 41,040 | Shares | Sole | 2026-02-13 | |
| 2024-12-31 | $239,677 | 9,326 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $394,781 | 23,782 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $471,816 | 24,561 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $389,609 | 16,474 | Shares | Sole | 2024-05-07 | |
| No filing history on record for this holder in this stock. | ||||||